Education
About Us
Working with TipRanks
Follow Us
Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
BCAX Stock Chart & Stats
$16.78
-$0.31(-1.97%)
At close: 4:00 PM EST
$16.78
-$0.31(-1.97%)
Day’s Range― - ―
52-Week Range$7.80 - $19.71
Previous CloseN/A
Volume80.52K
Average Volume (3M)442.77K
Market Cap
$919.24M
Enterprise Value$793.92M
Total Cash (Recent Filing)$290.17M
Total Debt (Recent Filing)$1.98M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Mar 26, 2026EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding54,781,950
10 Day Avg. Volume626,439
30 Day Avg. Volume442,774
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)1.93
Price to Sales (P/S)0.00
P/FCF Ratio-12.67
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.81
Forecast
1Y Price Target
$31.10Price Target Upside85.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.03
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 1 data showed nearly half of evaluable patients had confirmed tumor responses and a notable share achieved complete responses, suggesting deeper and more durable tumor control versus a key competitor's combination therapy.
Dosing StrategyManagement selected a 1500 mg weekly induction followed by less frequent maintenance for the pivotal head and neck study, balancing improved tolerability with sustained drug exposure to support competitive positioning.
FinancingAvailable cash fully funds the pivotal study through the confirmatory endpoint, reducing near-term financing risk and enabling uninterrupted execution of the registrational program.
Bears Say
Competitive RiskA crowded head and neck cancer landscape with multiple bispecific therapies and rival teams ahead on topline timelines creates first-mover and differentiation risk that could erode ficera's market opportunity.
Mechanism UncertaintyComparisons with cetuximab suggest the TGF‑β trap may contribute little to efficacy, raising the risk that TGF‑β–related safety liabilities could outweigh measurable benefit in late‑stage studies.
Safety ConcernsHigher dosing was associated with increased severe adverse events, including bleeding and anemia, which could limit physician adoption and patient persistence on therapy.
Bicara Therapeutics Inc. News
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $7.80 and its highest was $19.71 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Bicara Therapeutics Inc.’s market cap is $919.24M.
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
Bicara Therapeutics Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 23 days.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Bicara Therapeutics Inc. released its earnings results on Nov 18, 2025. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of -$0.541 by -$0.129.
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate is -0.67.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 54,781,950 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Bicara Therapeutics Inc. reported an EPS of -$0.67 in its last earnings report, missing expectations of -$0.541. Following the earnings report the stock price went up 3.455%.
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bicara Therapeutics Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.10 (85.34% Upside)
$31.10 (85.34% Upside)
Blogger Sentiment
Bullish
BCAX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.2%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.76%
12-Months-Change
Fundamentals
Return on Equity
-26.64%
Trailing 12-Months
Asset Growth
-18.98%
Trailing 12-Months
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
BCAX Stock 12 Month Forecast
Average Price Target
$31.10
▲(85.34% Upside)
Technical Analysis
Arbutus Biopharma
―
Bicycle Therapeutics
―
Relay Therapeutics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
17.68% Insiders
12.60% Mutual Funds
29.25% Other Institutional Investors
31.27% Public Companies and
Individual Investors